American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting

美国基因与细胞治疗学会（ASGCT）成立于1996年。ASGCT的使命是促进知识、意识和教育，从而发现和临床应用基因和细胞疗法来减轻人类疾病。我们的年会代表了社会的主要教育举措，并已CME认证的所有我们以前的14次会议。这一R13建议要求支持为受训人员提供旅费赠款。超过四分之一的成员是科学家在培训 致力于开发临床应用的基因技术。培训生参加年会是由一个优秀的教育计划，培训生旅行奖，并通过同行评审的优秀研究奖培训生的杰出科学成就的认可培养。在过去的十年中，ASGCT提供了470个旅行赠款和63个研究奖，其中近190个旅行赠款金是由美国国立卫生研究院在同一时间提供的R13补助金。旅行获奖者的教育机会包括特殊的全体演讲者，最先进的科学研讨会，以及审查各种主题当前思想的教育会议。除了领先的科学家和临床医生，该计划还包括来自FDA，OBA和NIH的伦理学家和代表，因此年轻的科学家可以深入了解与人类基因治疗和细胞治疗相关的合规性和伦理问题。学员是口头摘要和海报演示的积极主持人，顶级学员摘要在总统研讨会上得到认可。ASGCT会议的规模（约1，700名与会者）非常适合让年轻科学家接触该领域的领导者，同时也为学员提供机会，在基因和细胞治疗领域的首要会议上介绍他们的工作。美国国立卫生研究院对ASGCT年会的支持将使细胞和基因治疗领域的受训人员继续获得教育和专业发展，并有机会与该领域的领导者建立联系。 公共卫生相关性：美国基因与细胞治疗学会（ASGCT）正在为2012年5月第15届年会提交科学摘要的博士后研究员和学生寻求20项旅行奖。旅行奖颁发给申请该奖项并在同行评审过程中获得最高分的学生和博士后研究员。

DESCRIPTION (provided by applicant): The American Society of Gene & Cell Therapy (ASGCT) was founded in 1996. ASGCT's mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. Our Annual Meeting represents the major educational initiative of the Society and has been CME-accredited for all of our prior 14 meetings. This R13 proposal requests support for travel grants for trainees. Over 1/4 of our members are scientists-in-training working to develop clinically applicable gene- based technologies. Trainee participation in the Annual Meeting is fostered by an outstanding educational program, trainee travel awards, and recognition of outstanding scientific accomplishments through peer-reviewed trainee Excellence in Research Awards. Over the past decade, the ASGCT has offered 470 travel grants and 63 Research Awards, with almost 190 travel grants made possible by R13 grant awards from the NIH during that same time. Educational opportunities for travel awardees include exceptional plenary speakers, state-of-the-art scientific symposia, and educational sessions that review current thinking on a variety of topics. In addition to leading scientists and clinicians, the program includes ethicists and representatives from the FDA, OBA, and NIH so young scientists may gain insight into the compliance and ethical issues related to human gene therapy and cell therapy. Trainees are active presenters in oral abstract and poster presentations, and the top trainee abstracts are recognized at the Presidential Symposium. The size of the ASGCT meeting (approximately 1,700 participants) is ideally suited to expose young scientists to leaders in the field yet provide opportunities for trainees to present their work at the premier meeting in the field of gene and cell therapy. NIH support for the ASGCT Annual Meeting will allow continued educational and professional advancement of trainees in the field of cell and gene therapy and the opportunity to network with leaders in the field. PUBLIC HEALTH RELEVANCE: The American Society of Gene & Cell Therapy (ASGCT) is seeking funding for 20 travel awards for post-doctoral fellows and students who submit scientific abstracts for its 15th Annual Meeting in May 2012. Travel awards are given to students and post-doctoral fellows who apply for the awards and who receive the highest scores during the peer review process.